A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis

OBJECTIVE: Etrolizumab (rhuMAb β7, anti-β7, PRO145223) is a humanised monoclonal antibody targeting the β7 subunit of the heterodimeric integrins α4β7 and αEβ7, which are implicated in leucocyte migration and retention in ulcerative colitis (UC). This randomised phase I study evaluated the safety an...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Rutgeerts, Paul J, Fedorak, Richard N, Hommes, Daan W, Sturm, Andreas, Baumgart, Daniel C, Bressler, Brian, Schreiber, Stefan, Mansfield, John C, Williams, Marna, Tang, Meina, Visich, Jennifer, Wei, Xiaohui, Keir, Mary, Luca, Diana, Danilenko, Dimitri, Egen, Jackson, O'Byrne, Sharon
Формат: Artigo
Язык:Inglês
Опубликовано: BMJ Group 2013
Предметы:
Inflammatory Bowel Disease
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3711369/
https://ncbi.nlm.nih.gov/pubmed/22717454
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/gutjnl-2011-301769
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы